Search clinical trials for: IBI315

Total 357 results

Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Participants With Obesity or Overweight

Obesity Or Overweight

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Indolent Non-hodgkin Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI362 9 mg in Chinese Adults With Obesity

Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in HeFH Patients

Heterozygous Familial Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

Overweight/ Obesity

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization (STOP)

Precancerous Conditions | Oral Cavity Cancer | Mouth Neoplasm

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shenzhen People's Hospital

Recruiting

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Lipid Metabolism Disorders | Familial Hypercholesterolemia - Homozygous | Proprotein Convertase Subtilisin/Kexin 9

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Beijing Tsinghua Chang Gung Hospital

Unknown

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma | Portal Vein Tumor Thrombosis

China
Wuhan Union Hospital, China

Recruiting

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Overweight or Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Healthy Participants | Atopic Dermatitis Patients

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Healthy Subjects

China
Chunrui Li
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#

Relapsed/Refractory Multiple Myeloma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

Hematologic Malignancy

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

China
Sichuan Cancer Hospital and Research Institute
Innovent Biologics, Inc.

Unknown

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer
Taizhou Hospital

Unknown

CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients (CARTAI)

Thoracic Malignancies

China
Fujian Haixi Pharmaceuticals Co., Ltd.

Recruiting

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

Solid Tumors or Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
Shanghai Zhongshan Hospital

Not yet recruiting

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Henan Cancer Hospital

Not yet recruiting

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Gastric Cancer | Gastroesophageal-junction Cancer
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
The First Affiliated Hospital of Soochow University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Relapsed/Refractory Multiple Myeloma

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

Cancer, Solid Tumor

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Metastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI306 in Participants With Hypercholesterolemia

Hypercholesterolemia

China
Mian XI

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Evaluation of IBI302 Injection in nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

China

3

Subscribe